A team of surgeons in the University College Hospital (UCH), Ibadan, led by Prof. Olayinka Shittu, has successfully performed an intricate procedure to reconstruct a urethral stricture in a ...
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis. Investigators in South Korea demonstrated the benefit in a ...
The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...
NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...
Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
The committee noted that the clinical evidence showed Optilume to be effective in improving clinically relevant outcomes including anatomical success, peak flow rate and international prostate symptom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback